EVOK Stock Overview
Evoke Pharma, Inc. es una empresa farmacéutica especializada, centrada principalmente en el desarrollo y comercialización de medicamentos para el tratamiento de trastornos y enfermedades gastroenterológicas.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Evoke Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.59 |
| 52 Week High | US$2.42 |
| 52 Week Low | US$0.56 |
| Beta | 0.30 |
| 1 Month Change | -16.39% |
| 3 Month Change | -34.97% |
| 1 Year Change | -70.74% |
| 3 Year Change | -97.31% |
| 5 Year Change | -93.83% |
| Change since IPO | -99.58% |
Recent News & Updates
Recent updates
Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely
Jan 22
Evoke to get US patent for nasal spray Gimoti
Sep 20Evoke Pharma Q2 GAAP loss per share narrows, revenue up
Aug 10Evoke Pharma gets Canadian patent linked to Gimoti nasal spray
Jul 06Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?
Oct 22Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?
Jul 06Evoke Pharma announces positive findings from second GIMOTI market research study
Jun 15Evoke Pharma pops 8% after Gimoti listed in FDA Orange Book
Jun 08Evoke Pharma issued new U.S. patent covering methods of use for Gimoti
Jun 02Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit
Mar 14Evoke Pharma shares surge on positive findings from Gimoti market research study
Jan 13Evoke Pharma EPS beats by $0.02
Nov 10Shareholder Returns
| EVOK | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.8% | -0.6% | -0.8% |
| 1Y | -70.7% | 16.6% | 25.9% |
Rentabilidad frente al sector: EVOK obtuvo unos resultados inferiores a los del sector US Pharmaceuticals , que el año pasado arrojó un rendimiento del -3.7%.
Rentabilidad vs. Mercado: EVOK obtuvo unos resultados inferiores a los del mercado US, que fue del 22.3% el año pasado.
Price Volatility
| EVOK volatility | |
|---|---|
| EVOK Average Weekly Movement | 12.8% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: EVOKha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: EVOK(11%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de los valores de US.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 4 | Matt D'Onofrio | https://evokepharma.com |
Evoke Pharma, Inc, empresa farmacéutica especializada, se dedica principalmente al desarrollo y comercialización de medicamentos para el tratamiento de trastornos y enfermedades gastroenterológicas. Ofrece Gimoti, un aerosol nasal de metoclopramida para tratar los síntomas asociados a la gastroparesia diabética aguda y recurrente en adultos. La empresa comercializa sus productos a gastroenterólogos, especialistas en medicina interna, médicos de atención primaria y proveedores de atención sanitaria seleccionados.
Evoke Pharma, Inc. Fundamentals Summary
| EVOK fundamental statistics | |
|---|---|
| Market cap | US$4.96m |
| Earnings (TTM) | -US$7.79m |
| Revenue (TTM) | US$5.18m |
1.0x
P/S Ratio-0.6x
P/E RatioIs EVOK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EVOK income statement (TTM) | |
|---|---|
| Revenue | US$5.18m |
| Cost of Revenue | US$201.88k |
| Gross Profit | US$4.98m |
| Other Expenses | US$12.77m |
| Earnings | -US$7.79m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.92 |
| Gross Margin | 96.10% |
| Net Profit Margin | -150.41% |
| Debt/Equity Ratio | -193.8% |
How did EVOK perform over the long term?
See historical performance and comparison